AngioDynamics (ANGO) Q3 2023: MedTech Grows 17% as AngioVac Weakness Triggers Guidance Cut
MedTech momentum continued with 17% growth, but AngioVac underperformance forced a downward revision to annual guidance. The quarter highlighted strong execution in Arion and NanoKnife, while mechanical thrombectomy execution and inflationary pressures weighed on margins and profit outlook. Investors should focus on platform expansion and execution improvements as AngioDynamics navigates supply chain and product integration challenges into FY24.
Summary
- Mechanical Thrombectomy Miss: AngioVac softness drove a guidance cut despite robust AlphaVac and Arion growth.
- Margin Headwinds Persist: Inflation and supply chain disruptions eroded profitability, offsetting sales mix gains.
- Platform Expansion Focus: Clinical trial progress and international launches remain central to long-term growth strategy.
Business Overview
AngioDynamics develops, manufactures, and markets minimally invasive medical devices for vascular and oncology interventions. The company operates two main segments: MedTech, its high-growth, high-margin platform technologies (including Arion, AlphaVac, AngioVac, and NanoKnife), and MedDevice, its legacy device portfolio (angiographic products, ports, dialysis, and microwave). Revenue is generated through sales of disposable devices, capital equipment, and related products to hospitals and clinics worldwide.
Performance Analysis
AngioDynamics delivered 9% revenue growth in Q3, led by continued outperformance in MedTech, which grew 17% year over year and now comprises 28% of total sales. Arion, the company’s atherectomy platform, was a standout with 43% growth, while NanoKnife, the focal ablation oncology platform, delivered a 22% increase in disposable sales, reflecting strong adoption and clinical momentum.
However, mechanical thrombectomy platform performance was mixed. AlphaVac, the newer entrant, met expectations, but AngioVac declined 16% as hospital staffing constraints and execution issues weighed on procedure volume. The MedDevice segment rebounded 6%, aided by improvements in labor and freight costs, though gross margins were pressured by inflation and ongoing supply chain disruptions. The company ended the quarter with a $5.4 million backlog, reflecting component shortages that deferred approximately $3 million in revenue to Q4.
- Arion Platform Acceleration: Strong hospital adoption, below-the-knee procedure growth, and supply chain enhancements fueled robust performance.
- AngioVac Drag: Execution shortfalls and hospital labor complexity led to a sharp sales decline, impacting both margins and overall outlook.
- Margin Compression: Inflation in raw materials and labor, plus product mix shift, drove gross margin down 200 basis points year over year.
Adjusted net loss and EBITDA both declined versus the prior year, with profitability hampered by AngioVac weakness and higher-than-expected inflation. Despite these setbacks, management reiterated confidence in the long-term MedTech platform trajectory.
Executive Commentary
"While we are reducing our fiscal 2023 revenue expectations as a result of this AngioVac softness, which also flows down to impact our margin and EPS outlook, we remain very bullish about the mid-term and long-term prospects for our mechanical thrombectomy business."
Jim Clemmer, President and Chief Executive Officer
"Gross margins for the third quarter of fiscal 23 were positively impacted by increased production and sales mix of roughly 225 basis points. However, this benefit was offset by roughly 210 basis points of inflationary pressures, including 110 basis points of raw material inflation, 90 basis points of labor inflation, and 10 basis points of increased freight costs and depreciation from hardware placements."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech Platform Scaling
Arion, AlphaVac, and NanoKnife are the pillars of AngioDynamics’ high-growth MedTech strategy. Arion’s rapid growth is supported by hospital adoption, clinical differentiation, and supply chain improvements. NanoKnife’s clinical trial momentum and expanding indications are positioning it for a $700 million addressable market in prostate cancer alone.
2. Mechanical Thrombectomy Execution Reset
AngioVac’s underperformance exposed execution and market integration challenges. The company is revamping its commercial approach, with enhanced salesforce training, targeted messaging, and customer education to restore growth. AlphaVac is gaining traction, but the overall thrombectomy platform’s near-term growth expectations have been reset lower.
3. International Expansion and Regulatory Pathways
Western Europe is the initial focus for international launches of Arion and AlphaVac in FY24. Strengthening the global sales network and pursuing regulatory approvals in Canada, Latin America, Asia Pacific, and the Middle East are expected to drive incremental growth and diversify revenue streams.
4. Clinical Differentiation and Market Access
Ongoing IDE studies (PRESERVE, APEX, DIRECT) are central to expanding indications and reimbursement for NanoKnife and AlphaVac. Favorable recent publications and robust trial enrollment are building the clinical evidence base needed to accelerate adoption and market penetration.
5. Operational Resilience Amid Inflation
Management is actively managing supply chain volatility and inflationary cost pressures. While some improvement in freight and labor costs was noted, raw material inflation and component shortages remain persistent headwinds, with margin recovery dependent on further stabilization and operational leverage.
Key Considerations
AngioDynamics’ Q3 highlighted both the promise and complexity of transforming into a platform-focused MedTech company. Execution gaps in mechanical thrombectomy and persistent cost inflation tempered otherwise strong momentum in Arion and NanoKnife. The company is navigating a critical transition period, balancing near-term margin pressure with long-term platform expansion.
Key Considerations:
- Salesforce and Customer Training Overhaul: Enhanced commercial execution is essential to restore AngioVac momentum and unlock full platform synergies.
- Supply Chain Disruptions: Backlog and deferred revenue underscore the importance of securing component supply and mitigating raw material inflation.
- Clinical Trial Progress: Successful completion and publication of IDE studies will be crucial for regulatory approvals and expanding addressable markets.
- International Launches: Western Europe is the near-term priority, with broader global expansion needed to diversify growth and reduce US procedural risk.
- Margin Recovery Path: Inflation and product mix shifts require operational discipline to restore profitability as revenue grows.
Risks
Execution risk remains elevated as AngioDynamics integrates new product platforms and overhauls its commercial approach for mechanical thrombectomy. Persistent inflation and supply chain volatility could further pressure margins and delay revenue recognition. Regulatory hurdles, particularly for new indications and international launches, add uncertainty to the growth trajectory. Competitive dynamics in atherectomy and thrombectomy markets may intensify, challenging share gains and pricing power.
Forward Outlook
For Q4, AngioDynamics guided to:
- Clearing $3 million in deferred revenue tied to component shortages
- Sequential growth in AngioVac and continued strength in Arion and NanoKnife
For full-year 2023, management lowered guidance:
- Revenue: $338 million to $342 million (down from $342 million to $348 million)
- Adjusted EPS: Loss of $0.06 to loss of $0.01 (previously earnings of $0.01 to $0.06)
- Gross margin: 51% to 52% (down from 52.5% to 54.5%)
Management cited seasonal Q4 strength, backlog clearance, and ongoing platform growth as drivers for achieving the revised guidance range, with a focus on restoring AngioVac momentum and managing inflationary headwinds.
- Improved hospital staffing and supply chain conditions expected to aid Q4 topline
- Continued investment in R&D and commercial infrastructure to support platform growth
Takeaways
AngioDynamics’ transformation into a high-growth MedTech platform remains on track, but Q3 exposed the operational and commercial execution risks inherent in scaling new technologies.
- Platform Growth Outpaces Legacy: Arion and NanoKnife are delivering robust growth, but mechanical thrombectomy execution must improve to fully realize platform potential.
- Cost and Execution Challenges: Margin compression and AngioVac underperformance highlight the need for operational discipline and commercial realignment.
- Key Watchpoints Ahead: Investors should monitor backlog clearance, AngioVac sequential growth, and clinical trial milestones as indicators of execution and future upside.
Conclusion
AngioDynamics’ Q3 demonstrates the duality of platform-driven growth and operational complexity. While Arion and NanoKnife validate the MedTech strategy, AngioVac softness and cost pressures require immediate attention. The company’s long-term value hinges on successful execution of platform integration, international expansion, and clinical trial-driven market access.
Industry Read-Through
AngioDynamics’ results reflect broader MedTech industry themes: Supply chain volatility, inflation, and hospital staffing constraints remain key operational risks for device makers. The company’s experience with product integration and commercial execution highlights the challenges of scaling new platforms in competitive, procedure-driven markets. Clinical differentiation and regulatory progress are increasingly critical for winning share in high-growth segments like atherectomy and thrombectomy. Investors across the sector should closely track margin recovery strategies and the pace of international expansion as bellwethers for MedTech resilience and growth in a volatile macro environment.